H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
16 th Congress of the <strong>European</strong> Hemato<strong>lo</strong>gy Associat<strong>io</strong>n<br />
28. Watowich SS, Wu H, Soco<strong>lo</strong>vsky M, Klingmuller U,<br />
Constantinescu SN, Lodish HF. Cytokine receptor signal<br />
transduct<strong>io</strong>n and the control of hematopoietic cell deve<strong>lo</strong>pment.<br />
Ann Rev Cell Dev B<strong>io</strong>l. 1996;12:91-128.<br />
29. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton<br />
MR, et al. JAK2 exon 12 mutat<strong>io</strong>ns in polycythemia vera and<br />
id<strong>io</strong>pathic erythrocytosis. N Engl J Med. 2007 Feb 1;356(5):<br />
459-68.<br />
30. Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR,<br />
Girodon F, et al. Molecular and clinical features of the mye<strong>lo</strong>proliferative<br />
neoplasm associated with JAK2 exon 12 mutat<strong>io</strong>ns.<br />
B<strong>lo</strong>od. 2011 Jan 11 [Epub ahead of print as doi:]<br />
31. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA,<br />
Wadleigh M, et al. MPL515 mutat<strong>io</strong>ns in mye<strong>lo</strong>proliferative<br />
and other mye<strong>lo</strong>id disorders: a study of 1182 patients. B<strong>lo</strong>od.<br />
2006 Nov 15;108(10):3472-6.<br />
32. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo<br />
M, et al. MPLW515L Is a Novel Somatic Activating Mutat<strong>io</strong>n<br />
in Mye<strong>lo</strong>fibrosis with Mye<strong>lo</strong>id Metaplasia. PLoS Med. 2006<br />
Jul 18;3(7):e270.<br />
33. Staerk J, Lacout C, Smith SO, Vainchenker W, Constantinescu<br />
SN. An amphipathic motif at the transmembrane-cytoplasmic<br />
junct<strong>io</strong>n prevents autonomous activat<strong>io</strong>n of the thrombopoietin<br />
receptor. B<strong>lo</strong>od. 2006;107:1864-71.<br />
34. Chaligne R, James C, Tonetti C, Besancenot R, Le Couedic JP,<br />
Fava F, et al. Evidence for MPL W515L/K mutat<strong>io</strong>ns in<br />
hematopoietic stem cells in primitive mye<strong>lo</strong>fibrosis. B<strong>lo</strong>od.<br />
2007 Nov 15;110(10):3735-43.<br />
35. Pecquet C, Staerk J, Chaligne R, Goss V, Lee KA, Zhang X, et<br />
al. Induct<strong>io</strong>n of mye<strong>lo</strong>proliferative disorder and mye<strong>lo</strong>fibrosis<br />
by thrombopoietin receptor W515 mutants is mediated by<br />
cytosolic tyrosine 112 of the receptor. B<strong>lo</strong>od. 2010 Dec<br />
8;115(5):1037-48.<br />
36. Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh<br />
A, et al. Familial essential thrombocythemia associated with<br />
a dominant-positive activating mutat<strong>io</strong>n of the c-MPL gene,<br />
which encodes for the receptor for thrombopoietin. B<strong>lo</strong>od.<br />
2004 Jun 1;103(11):4198-200.<br />
37. Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford<br />
D, et al. MPL mutat<strong>io</strong>ns in mye<strong>lo</strong>proliferative disorders: analysis<br />
of the PT-1 cohort. B<strong>lo</strong>od. 2008 Jul 1;112(1):141-9.<br />
38. Pietra D, Brisci A, Rumi E, Boggi S, Elena C, Pietrelli A, et al.<br />
Deep sequencing reveals double mutat<strong>io</strong>ns in cis of MPL exon<br />
10 in mye<strong>lo</strong>proliferative neoplasms. Haemato<strong>lo</strong>gica. 2011<br />
Jan 12.<br />
39. Malinge S, Ragu C, Della-Valle V, Pisani D, Constantinescu SN,<br />
Perez C, et al. Activating mutat<strong>io</strong>ns in human acute megakaryoblastic<br />
leukemia. B<strong>lo</strong>od. 2008 Nov 15;112(10):4220-6.<br />
40. Qian H, Buza-Vidas N, Hyland CD, Jensen CT, Antonchuk J,<br />
Mansson R, et al. Critical role of thrombopoietin in maintaining<br />
adult quiescent hematopoietic stem cells. Cell Stem Cell.<br />
2007 Dec 13;1(6):671-84.<br />
41. Yoshihara H, Arai F, Hosokawa K, Hagiwara T, Takubo K,<br />
Nakamura Y, et al. Thrombopoietin/MPL signaling regulates<br />
hematopoietic stem cell quiescence and interact<strong>io</strong>n with the<br />
osteoblastic niche. Cell Stem Cell. 2007 Dec 13;1(6):685-97.<br />
42. de Graaf CA, Kauppi M, Baldwin T, C DH, Metcalf D,<br />
Willson TA, et al. Regulat<strong>io</strong>n of hematopoietic stem cells by<br />
their mature progeny. Proc Natl Acad Sci U S A. 2010 Nov 29.<br />
[Epub ahead of print as doi:]<br />
43. Moliterno AR, Spivak JL. Posttranslat<strong>io</strong>nal processing of the<br />
thrombopoietin receptor is impaired in polycythemia vera.<br />
B<strong>lo</strong>od. 1999 Oct 15;94(8):2555-61.<br />
44. Moliterno AR, Williams DM, Rogers O, Spivak JL. Molecular<br />
mimicry in the chronic mye<strong>lo</strong>proliferative disorders: reciprocity<br />
between quantitative JAK2 V617F and Mpl express<strong>io</strong>n.<br />
B<strong>lo</strong>od. 2006 Aug 15.<br />
45. Girardot M, Pecquet C, Boukour S, Knoops L, Ferrant A,<br />
Vainchenker W, et al. miR-28 is a thrombopoietin receptor targeting<br />
microRNA detected in a fract<strong>io</strong>n of mye<strong>lo</strong>proliferative<br />
neoplasm patient platelets. B<strong>lo</strong>od. 2010 Jul 22;116(3):437-45.<br />
46. Besancenot R, Chaligne R, Tonetti C, Pasquier F, Marty C,<br />
Lecluse Y, et al. A senescence-like cell-cycle arrest occurs during<br />
megakaryocytic maturat<strong>io</strong>n: implicat<strong>io</strong>ns for phys<strong>io</strong><strong>lo</strong>gical<br />
and patho<strong>lo</strong>gical megakaryocytic proliferat<strong>io</strong>n. PLoS B<strong>io</strong>l.<br />
2010;8(9).<br />
47. Dahlen DD, Broudy VC, Drachman JG. Internalizat<strong>io</strong>n of the<br />
thrombopoietin receptor is regulated by 2 cytoplasmic<br />
motifs. B<strong>lo</strong>od. 2003 Jul 1;102(1):102-8.<br />
48. Royer Y, Staerk J, Costuleanu M, Courtoy PJ, Constantinescu<br />
SN. Janus kinases affect thrombopoietin receptor cell surface<br />
<strong>lo</strong>calizat<strong>io</strong>n and stability. J B<strong>io</strong>l Chem. 2005;280:27251-61.<br />
49. Tiedt R, Coers J, Ziegler S, Wiestner A, Hao-Shen H,<br />
Bornmann C, et al. Pronounced thrombocytosis in transgenic<br />
mice expressing reduced levels of Mpl in platelets and terminally<br />
differentiated megakaryocytes. B<strong>lo</strong>od. 2009 Feb<br />
19;113(8):1768-77.<br />
50. Lannutti BJ, Epp A, Roy J, Chen J, Josephson NC. Incomplete<br />
restorat<strong>io</strong>n of Mpl express<strong>io</strong>n in the mpl-/- mouse produces<br />
partial correct<strong>io</strong>n of the stem cell-repopulating defect and paradoxical<br />
thrombocytosis. B<strong>lo</strong>od. 2009 Feb 19;113(8):1778-85.<br />
51. Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD,<br />
Jr., et al. Novel mutat<strong>io</strong>ns in the inhibitory adaptor protein<br />
LNK drive JAK-STAT signaling in patients with mye<strong>lo</strong>proliferative<br />
neoplasms. B<strong>lo</strong>od. 2010 Aug 12;116(6):988-92.<br />
52. Baran-Marszak F, Magdoud H, Desterke C, Alvarado A,<br />
Roger C, Harel S, et al. Express<strong>io</strong>n level and differential JAK2-<br />
V617F-binding of the adaptor protein Lnk regulates JAK2mediated<br />
signals in mye<strong>lo</strong>proliferative neoplasms. B<strong>lo</strong>od. Dec<br />
23;116(26):5961-71.<br />
53. Rudd CE. Lnk adaptor: novel negative regulator of B cell lymphopoiesis.<br />
Sci STKE. 2001 Jun 5;2001(85):pe1.<br />
54. Takaki S, Morita H, Tezuka Y, Takatsu K. Enhanced hematopoiesis<br />
by hematopoietic progenitor cells lacking intracellular adaptor<br />
protein, Lnk. J Exp Med. 2002 Jan 21;195(2):151-60.<br />
55. Simon C, Dondi E, Chaix A, de Sepulveda P, Kubiseski TJ,<br />
Varin-Blank N, et al. Lnk adaptor protein down-regulates specific<br />
Kit-induced signaling pathways in primary mast cells.<br />
B<strong>lo</strong>od. 2008 Nov 15;112(10):4039-47.<br />
56. Seita J, Ema H, Ooehara J, Yamazaki S, Tadokoro Y, Yamasaki<br />
A, et al. Lnk negatively regulates self-renewal of hematopoietic<br />
stem cells by modifying thrombopoietin-mediated signal<br />
transduct<strong>io</strong>n. Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):<br />
2349-54.<br />
57. Tong W, Lodish HF. Lnk inhibits Tpo-mpl signaling and Tpomediated<br />
megakaryocytopoiesis. J Exp Med. 2004 Sep<br />
6;200(5):569-80.<br />
58. Gery S, Gueller S, Chumakova K, Kawamata N, Liu L,<br />
Koeffler HP. Adaptor protein Lnk negatively regulates the<br />
mutant MPL, MPLW515L associated with mye<strong>lo</strong>proliferative<br />
disorders. B<strong>lo</strong>od. 2007 Nov 1;110(9):3360-4.<br />
59. Bersenev A, Wu C, Balcerek J, Jing J, Kundu M, B<strong>lo</strong>bel GA, et<br />
al. Lnk constrains mye<strong>lo</strong>proliferative diseases in mice. J Clin<br />
Invest. 2010 Jun 1;120(6):2058-69.<br />
60. Lasho TL, Pardanani A, Tefferi A. LNK mutat<strong>io</strong>ns in JAK2<br />
mutat<strong>io</strong>n-negative erythrocytosis. N Engl J Med. 2010 Sep 16;<br />
363(12):1189-90.<br />
61. Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A.<br />
LNK mutat<strong>io</strong>n studies in blast-phase mye<strong>lo</strong>proliferative neoplasms,<br />
and in chronic-phase disease with TET2, IDH, JAK2<br />
or MPL mutat<strong>io</strong>ns. Leukemia. 2010 Oct;24(10):1713-8.<br />
62. Schmidt MH, Dikic I. The Cbl interactome and its funct<strong>io</strong>ns.<br />
Nat Rev Mol Cell B<strong>io</strong>l. 2005 Dec;6(12):907-18.<br />
63. Swaminathan G, Tsygankov AY. The Cbl family proteins:<br />
ring leaders in regulat<strong>io</strong>n of cell signaling. J Cell Phys<strong>io</strong>l. 2006<br />
Oct;209(1):21-43.<br />
64. Saur SJ, Sangkhae V, Geddis AE, Kaushansky K, Hitchcock IS.<br />
Ubiquitinat<strong>io</strong>n and degradat<strong>io</strong>n of the thrombopoietin receptor<br />
c-Mpl. B<strong>lo</strong>od. Feb 11;115(6):1254-63.<br />
65. Naramura M, Nandwani N, Gu H, Band V, Band H. Rapidly<br />
fatal mye<strong>lo</strong>proliferative disorders in mice with delet<strong>io</strong>n of<br />
Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem<br />
cells. Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16274-9.<br />
66. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire<br />
C, et al. Frequent CBL mutat<strong>io</strong>ns associated with 11q<br />
acquired uniparental disomy in mye<strong>lo</strong>proliferative neoplasms.<br />
B<strong>lo</strong>od. 2009 Jun 11;113(24):6182-92.<br />
67. Beer PA, Delhommeau F, LeCouedic JP, Dawson MA, Chen E,<br />
Bareford D, et al. Two routes to leukemic transformat<strong>io</strong>n<br />
after a JAK2 mutat<strong>io</strong>n-positive mye<strong>lo</strong>proliferative neoplasm.<br />
B<strong>lo</strong>od. 2010 Apr 8;115(14):2891-900.<br />
68. Stegelmann F, Bullinger L, Griesshammer M, Holzmann K,<br />
Habdank M, Kuhn S, et al. High-resolut<strong>io</strong>n single-nucleotide<br />
polymorphism array-profiling in mye<strong>lo</strong>proliferative neoplasms<br />
identifies novel genomic aberrat<strong>io</strong>ns. Haemato<strong>lo</strong>gica.<br />
2010 Apr;95(4):666-9.<br />
69. Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, Braun BS, et<br />
al. Somatic inactivat<strong>io</strong>n of Nf1 in hematopoietic cells results<br />
in a progressive mye<strong>lo</strong>proliferative disorder. B<strong>lo</strong>od. 2004 Jun<br />
1;103(11):4243-50.<br />
70. Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I,<br />
Yoshimura A. CIS3/SOCS-3 suppresses erythropoietin (EPO)<br />
signaling by binding the EPO receptor and JAK2. J B<strong>io</strong>l Chem.<br />
2000 Sep 22;275(38):29338-47.<br />
71. Hortner M, Nielsch U, Mayr LM, Heinrich PC, Haan S. A new<br />
high affinity binding site for suppressor of cytokine signaling-<br />
3 on the erythropoietin receptor. Eur J B<strong>io</strong>chem. 2002<br />
May;269(10):2516-26.<br />
| 252 | Hemato<strong>lo</strong>gy Educat<strong>io</strong>n: the educat<strong>io</strong>n programme for the annual congress of the <strong>European</strong> Hemato<strong>lo</strong>gy Associat<strong>io</strong>n | 2011; 5(1)